Prolyl Hydroxylase 3 (Phd3) Is a Therapeutic Target in Isocitrate Dehydrogenase 1 (IDH1) Mutated Acute Myeloid Leukemia
Chaturvedi A, Cruz MMA, Goparaju R, Gabdoulline R, Schottmann R, Goerlich K, Kloos A, Thol F, Geffers R, Mougiakakos D, Carmeliet P, Ganser A, Heuser M (2018)
Publication Type: Conference contribution
Publication year: 2018
Journal
Publisher: AMER SOC HEMATOLOGY
City/Town: WASHINGTON
Conference Proceedings Title: BLOOD
Event location: San Diego, CA
DOI: 10.1182/blood-2018-99-110425
Authors with CRIS profile
Involved external institutions
Medizinische Hochschule Hannover (MHH) / Hannover Medical School
Germany (DE)
Flanders Institute for Biotechnology / Vlaams Instituut voor Biotechnologie (VIB)
Belgium (BE)
Helmholtz-Zentrum für Infektionsforschung (HZI)
Germany (DE)
Germany (DE)
Flanders Institute for Biotechnology / Vlaams Instituut voor Biotechnologie (VIB)
Belgium (BE)
Helmholtz-Zentrum für Infektionsforschung (HZI)
Germany (DE)
How to cite
APA:
Chaturvedi, A., Cruz, M.M.A., Goparaju, R., Gabdoulline, R., Schottmann, R., Goerlich, K.,... Heuser, M. (2018). Prolyl Hydroxylase 3 (Phd3) Is a Therapeutic Target in Isocitrate Dehydrogenase 1 (IDH1) Mutated Acute Myeloid Leukemia. In BLOOD. San Diego, CA, US: WASHINGTON: AMER SOC HEMATOLOGY.
MLA:
Chaturvedi, Anuhar, et al. "Prolyl Hydroxylase 3 (Phd3) Is a Therapeutic Target in Isocitrate Dehydrogenase 1 (IDH1) Mutated Acute Myeloid Leukemia." Proceedings of the 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA WASHINGTON: AMER SOC HEMATOLOGY, 2018.
BibTeX: Download